IMPROVING HbA1c CONTROL AMONG NEWLY INITIATED INSULIN TYPE II DIABETES MELLITUS PATIENTS IN KLINIK KESIHATAN KELANA JAYA
DOI:
https://doi.org/10.63719/qbulletin.v1i33.308Keywords:
HbA1c, Insulin initiation, Multidisciplinary teamAbstract
HbA1c is an important indicator of glycaemic control as it correlates with the risk of long-term diabetes complications. In 2017, only 17.4% of Type II Diabetes Mellitus (T2DM) patients at Klinik Kesihatan Kelana Jaya (KKKJ) newly initiated on insulin achieved at least a 1% reduction in HbA1c after six months. This contributed to 40.9% of patients developing diabetic nephropathy, 48.6% experiencing diabetic neuropathy, and 20.1% being diagnosed with diabetic retinopathy. Our study indicator is the percentage of T2DM patients who achieved at least a 1% reduction in HbA1c six months after insulin initiation. A target of 80% was set, based on consensus reached during 2018 Non-Communicable Disease (NCD) meeting at KKKJ. This quality improvement study employed a universal sampling method from July 2018 to July 2020. Data were collected using questionnaires distributed to healthcare professionals (HCPs), an audit checklist, and a patient assessment form completed during clinic visits. The data were analysed using Microsoft Excel. During the verification study, the achievement rate was 23.8%. The identified contributing factors to poor HbA1c control were poor patient adherence to insulin, lack of awareness among HCPs regarding the latest insulin guidelines, insufficient coordination among the multidisciplinary team, lack of self-monitoring of blood glucose and self-adjustment of insulin doses, and patient’s non-adherence to lifestyle interventions. Several strategies were introduced, including the “One Sweet Centre,” which involved a multidisciplinary team comprising a medical officer, pharmacist, dietitian, diabetes educator, and occupational therapist. Additionally, glucometers were loaned to patients with financial difficulties. Phone consultations and a drive-through service were offered during the Movement Control Order (MCO) period of the Covid-19 pandemic. Post-intervention results showed that the percentage of T2DM patients achieving at least a 1% reduction in HbA1C after six months of insulin initiation increased from 23.8% to 50% in cycle one, 70% in cycle two, and 83.3% in cycle three. Moving forward, we plan to share our remedial actions with other clinics and expand this initiative by setting up a peer support club and collaborating with Non-Governmental Organisations (NGOs) to empower the community.
References
1. Portal Rasmi Kementerian Kesihatan Malaysia [Internet]. [cited 2024 Mar 7]. Available from: https://www.moh.gov.my/index.php/database_stores/store_view_page/1/2298
2. Ministry of Health Malaysia. Practical Guide to Insulin Therapy in Type 2 Diabetes Mellitus. Putrajaya: Ministry of Health Malaysia; 2010.
3. Disease Control Division, Ministry of Health Malaysia. National Diabetes Registry Report 2020. Putrajaya: Ministry of Health Malaysia; 2020.
4. Variation in insulin usage between states among Type 2 Diabetes patients attending government health clinics in Malaysia [Internet]. Med J Malaysia. 2015;70(Suppl 1). [cited 2024 Mar 7]. Available from: https://e-mjm.org/2015/v70s1/mjm-sept-suppl-2181.html
5. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization; 2011. PMID: 26158184.
6. Tsai ST, Pathan F, Ji L, Yeung VTF, Chadha M, Suastika K, et al. First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011 Sep;3(3):208–16.
7. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: What have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23(6):441–54.
8. Brož J, Janíčková Žďárská D, Štěpánová R, Kvapil M, Zourek J. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study). Diabetes Ther. 2019;10(5):1887–1901. doi:10.1007/s13300-019-0676-z.
9. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405–12.
10. Unnikrishnan RI, Mohan V. Importance of controlling diabetes early: the concept of "metabolic memory", "legacy effect" and the case for early insulinisation. J Assoc Physicians India. 2011 Apr;59(Suppl):8–12.
11. Mustapha FI, Md Isa Z, Lye MS. What are the direct medical costs of managing Type 2 Diabetes Mellitus in Malaysia? Med J Malaysia [Internet]. 2017 Oct [cited 2019 Nov 11];72(5):271–7. Available from: http://www.e-mjm.org/2017/v72n5/medical-cost-of-diabetes.pdf
12. Viana LV, Leitão CB, Kramer CK, Zucatti ATN, Jezini DL, Felício J, et al. Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study. BMJ Open. 2013;3(9):e003336.
13. Mafauzy M, Hussein Z, Chan SP. The status of diabetes control in Malaysia: results of DiabCare 2008. Med J Malaysia. 2011 Aug;66(3):175–81. PMID: 22111435.
14. Chan JCN, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SRG, Hancu N, et al. Multifaceted determinants for achieving glycemic control the international diabetes management practice study (IDMPS). Diabetes Care. 2009 Feb;32(2):227–33.
15. Professional Practice Committee. Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S3.
16. Farsaei S, Radfar M, Heydari Z, Abbasi F, Qorbani M. Insulin adherence in patients with diabetes: risk factors for injection omission. Prim Care Diabetes. 2014;8(4):338–45.
17. Gherman A, Schnur J, Montgomery G, Sassu R, Veresiu I, David D. How are adherent people more likely to think? A meta-analysis of health beliefs and diabetes self-care. Diabetes Educ. 2011;37(3):392–408.
18. Sarbacker GB, Urteaga EM. Adherence to insulin therapy. Diabetes Spectr. 2016;29(3):166–70.
19. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14(12):1081–1087.
20. Funnell MM. Overcoming Barriers to the Initiation of Insulin Therapy. Clin Diabetes [Internet]. 2007;25(1):36–38. Available from: http://diabetesjournals.org/clinical/article-pdf/25/1/36/320977/0036.pdf
21. Rodriguez-Gutierrez R, Lipska KJ, McCoy RG. Intensive glycemic control in type 2 diabetes mellitus—a balancing act of latent benefit and avoidable harm: a teachable moment. JAMA Intern Med. 2016;176(3):300–301.
22. Machry RV, Pedroso HU, Vasconcellos LS, Nunes RR, Evaldt CA, Yunes Filho EB, et al. Multifactorial intervention for diabetes control among older users of insulin. Rev Saude Publica. 2018;52:60.
23. Sherman BW. Novel devices for delivering diabetes medications: their value and some coverage considerations. Manag Care. 2017;26(3):42–45.
24. Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139–49.
25. Mustapha FI, Md Isa Z, Lye MS. What are the direct medical costs of managing Type 2 Diabetes Mellitus in Malaysia? Med J Malaysia [Internet]. 2017 Oct [cited 2019 Nov 11];72(5):271–7. Available from: http://www.e-mjm.org/2017/v72n5/medical-cost-of-diabetes.pdf


